CASE SERIES  PEER REVIEWED | OPEN ACCESS

Safe and effective use of cabozantinib and nivolumab in stabilizing disease progression of tissue sarcoma after multiple lines of standard therapy

My Linh D Vu, Andrew Berman, Erica Kao, Kristin Stoll, Lauren Lee

ABSTRACT

Introduction: Soft-tissue sarcomas (STS) are a rare and varied group of tumors with limited treatment options. In recent years, immune checkpoint inhibitors have demonstrated efficacy in an increasing number of solid tumors. Nivolumab, a PD1-inhibitor, demonstrates improved overall survival (OS) and progression-free survival (PFS) in renal cell carcinoma, melanoma, and gastrointestinal stromal tumor (GIST). The tyrosine kinase inhibitor (TKI), cabozantinib, demonstrates an antitumor effect in osteosarcoma and Ewing sarcoma.

Case Series: Here we describe two patients with recurrent and refractory STS. Both patients failed multiple lines of conventional therapy including neoadjuvant radiation, surgical resection, and palliative chemotherapy before achieving partial response with combination cabozantinib and nivolumab.

Conclusion: These cases demonstrate the safety and efficacy of using combination nivolumab and cabozantinib in treatment of STS warranting further investigation of immunotherapy treatment.

Keywords: Cabozantinib, Immunotherapy, Metastatic sarcoma, Nivolumab

INTRODUCTION

Soft-tissue sarcomas (STS) are a rare and heterogeneous group of mesenchymal malignant tumors accounting for <1% of adult cancers representing more than 100 histopathologic subtypes and 60 distinct diagnoses, making treatment challenging [1]. Despite aggressive treatment, the five-year survival rates for STS vary between 15–81% [2]. Standard of care consists of neoadjuvant and adjuvant cytotoxic chemotherapy with anthracycline-based regimens, such as doxorubicin, ifosfamide, and mesna (AIM). While anthracycline-based regimens are recommended for initial therapy, second-line treatment is targeted to specific sarcoma types given the wide array of mutational variations and subtypes [3].

Undifferentiated pleomorphic sarcoma (UPS) represents approximately 20% of the STS subtypes [4]. It is an aggressive pleomorphic malignancy without identifiable differentiation or specific morphologic immunohistochemistry markers for cell lineage. As such, it is a diagnosis of exclusion. Undifferentiated pleomorphic sarcoma tumors most commonly occur in the head, neck, retroperitoneum, and extremities [5]. In the metastatic setting, despite cytotoxic agents, survival rates for UPS continue to hover between 12 and 18 months. Similarly, spindle cell sarcoma (SCS) is a similar subtype of STS characterized by spindle-shaped morphology on...
CASE SERIES

Case 1

A 39-year-old Caucasian woman presented with a progressively enlarging painful mass on the left knee. Computed tomography (CT) imaging demonstrated a 6.2 × 3.5 × 5.3 cm bony lesion in the lateral femoral condyle. Pathology identified a malignant hypercellular spindle-cell lesion with a brisk mitotic rate favoring high-grade fibrosarcoma, osteosarcoma, or differentiated component chondrosarcoma. Genomic testing revealed a loss of CDKN2A/B and a mutation of PTEN, which is found in the RAS/MAPK signaling pathway. Initial histologic staining was significant for TLE-1. SYT gene re-arrangement was negative by fluorescence in situ hybridization (FISH) and molecular testing was BCOR negative, therefore not consistent with synovial sarcoma or Ewing-like sarcoma, respectively. Positron emission tomography-computed tomography (PET-CT) did not detect distant disease, and she was diagnosed with stage IIA, pT1a No Mo G3 high-grade spindle cell sarcoma (Figure 1). She underwent neoadjuvant methotrexate, doxorubicin, and cisplatin followed by resection. Surgical tissue showed only 20% necrosis suggesting a high risk of recurrence therefore she received 4 cycles of adjuvant ifosfamide (10 gm/m²).

A year following her initial diagnosis, she presented with chest wall pain. A CT chest revealed a right lower lobe pleural-based mass measuring up to 2.7 × 1.1 × 2.9 cm suggesting recurrent disease. A biopsy of the lesion confirmed recurrent disease and she underwent surgical resection with curative intent. However, at the time of surgery, diaphragmatic involvement was discovered, preventing full removal. Tissue confirmed a similar histologic appearance with an evolved de-differentiation raising the possibility of UPS. She underwent 9 cycles of regorafenib before discontinuing for progressive disease with enlarging solid pleural and chest wall masses. Therapy with gemcitabine and docetaxel was initiated but complicated by severe toxicities including myelosuppression requiring hospitalization. An attempt with monotherapy with Gemcitabine continued to have significant toxicities and progressive disease with a greater than 20% increase in tumor burden.

She was referred to and evaluated for clinical trials at a cancer center of excellence, for which a phase 1 oral checkpoint inhibitor was offered even though her PD-L1 tumor proportion score of 0%. She ultimately opted to continue therapy locally and was started on similar treatment with nivolumab and cabozantinib. While on combined therapy, she received surveillance imaging at three-month intervals. She tolerated combined nivolumab and cabozantinib therapy well with only grade 1 toxicity of diarrheal symptoms that was manageable symptomatically or with adjustment in dosages since half-life of nivolumab and cabozantinib is 25 days and 99 hours, respectively [15].

Although STS continues to be difficult to treat, Movva et al. assessed PD-L1 expression in UPS cases and demonstrated that 70% had high PD-L1 expression [1]. Additionally, Wunder et al. recently demonstrated better overall survival with hazard ratio of 6.27 in patient exhibiting high compared to low PD-L1 level [16]. The strong immune presence offers the promise of a target for immune therapy and justifies their use, particularly for salvage therapy for progressive, metastatic disease. Here, we discuss the use of nivolumab and cabozantinib in two cases of refractory, progressive STS by demonstrating both safety and effective disease response.
and dominant right lung nodule decreased from $6.4 \times 3.3$ cm to $6.2 \times 2.5$ cm, representing an approximate 25% size reduction. She achieved a maximal response of approximately 30% decrease in tumor burden and stable disease achieved for almost eight months until the disease again progressed (Figure 2). She then opted to discontinue treatment and pursue hospice and passed shortly after.

![Figure 1](image1.jpg)

Figure 1: Excision of left knee mass (H&E). (A) 10×: Low power view of a spindle-cell neoplasm with fascicular growth pattern and prominent compressed blood vessels. Scale 100 µm at bottom left (green). (B) 40×: Higher power view of the relatively uniform spindle cells in fascicles. Scale 50 µm at bottom left (green).

![Figure 2](image2.jpg)

Figure 2: Right chest wall mass stability from February 2021 to August 2021. (A) Mass measuring up to $64.1 \times 32.5$ mm in February 2021. (B) Mass measuring up to $61.6 \times 24.7$ mm August 2021.

Case 2

A 53-year-old African American male presented with an enlarging mass on the right lower leg. Initial X-rays noted a 0.9 cm soft tissue mass that appeared suspicious for intramuscular hematoma on ultrasound. Histology of surgically drained tissue was concerning for malignancy. Magnetic resonance imaging (MRI) showed a $6.1 \times 4.8 \times 2.6$ cm mass anterior to the distal tibia ultimately staged as cT2 No Mo G3, resulting in Stage IIIA diagnosis (Figure 3). Immunohistochemistry staining demonstrated UPS given no clear line of differentiation and high Ki67 expression associated with rapid cell proliferation and growth (Figure 4). Genomic testing revealed a FOXP1-TL1X fusion along with mutation of TP53, HRAS, and loss of NF1.

He received neoadjuvant radiation and resection with negative margins. No adjuvant therapy was administered, and surgical tissue showed 5% necrosis. Surveillance PET-CT seven months later detected a recurrence of disease with new pulmonary lesions. He underwent palliative AIM for 6 cycles but discontinued when disease progressed on imaging. Pathology confirmed recurrent disease with similar histologic characteristics and PD-L1 tumor portion score was 30%. He received palliative Docetaxel/Gemcitabine for 6 cycles until disease again progressed with an over 30% size increase of the pulmonary nodules in both upper lobes and right middle lobe. He quickly then progressed through pazopanib and trabectedin in the span of three months and his disease burden increased over 40%.

![Figure 3](image3.jpg)

Figure 3: Right lower extremity mass measuring up to 60.5 (A) x 36.6 (B) mm anterior to the distal tibia, staged as cT2 No Mo G3.

![Figure 4](image4.jpg)

Figure 4: Excision of right lower leg mass (H&E). (A) 10×: Low power view of an atypical spindle cell population with pleomorphic nuclei and abundant palely eosinophilic cytoplasm. Scale 100 µm at bottom left (green). (B) 40×: Higher power view of marked nuclear pleomorphism with scattered atypical mitoses. Scale 50 µm at bottom left (green).

Considering his PD-L1 tumor portion score of 30%, nivolumab was initiated. Shortly after, interval CT showed possible progression in size of pulmonary nodules, prompting the addition of cabozantinib. The patient had minimal side effects on combination nivolumab and cabozantinib only to include palmar...
plantar erythrodysesthesia that was well managed with topical emollients and steroids. Positron emission tomography-computed tomography imaging showed partial/mix response of dominant pulmonary nodules, but mediastinal lymph nodes reduced by greater than 30% (Figure 5). He achieved disease stability on combination nivolumab/cabozantinib therapy with symptomatic improvement of cough and shortness of breath up to nine months before disease again progressed. He was trialed briefly on one cycle of regorafenib with poor tolerance and no benefit, therefore he transitioned electively to hospice care.

Figure 5: Right upper lobe lung mass stability from March 2021 to May 2021 while on nivolumab and cabozantinib. (A) March 2021 chest CT with right anterior mass measuring up to 61.8 × 41.5 mm and right posterior mass measuring up to 38.7 × 48.0 mm. (B) May 2021 chest CT with right anterior mass measuring up to 63.7 × 41.9 mm and right posterior mass measuring up to 31.9 × 39.4 mm.

DISCUSSION

In both cases, stable disease and even partial response was achieved for over six months after failure of 4–5 lines of prior therapy. Both patients had high-grade localized tumors that recurred after resection with negative margins resulting in metastases to the lungs, a common site for metastatic STS [17]. This suggests the combination of nivolumab and cabozantinib has a proven safety profile and demonstrates good potential in treatment-resistant STS warranting further investigation in clinical trials. Next generation sequencing revealed that both patients had dysregulation of the cell cycle, CDKN2A/B in case 1 and TP53 in case 2, both of which are not infrequently identified with UPS. As previously mentioned, CDKN2A is a poor prognostic mutation in STS therefore it is impressive that our first patient was able to achieve disease stability for months on nivolumab/cabozantinib therapy. Other mutations noted in these two patients such as PTPN11 and HRAS have limited data in sarcomas but are associated with poor overall survival in other cancers including bladder and breast cancer [18, 19]. Interestingly, high tumor mutational burden (TMB) is often predictive of better response to immunotherapy [8]. However, both of our patients had low TMB, suggesting multiple mechanisms at play. Therefore, one could postulate that other patients with higher TMB may obtain even more favorable response from combined anti-PD1 and TKI therapy.

Tissue pathology of both patients was positive for CD99, which suggests Ewing-like sarcoma [20] but BCOR was negative by molecular testing. Given the similar cellular expression and promising results with cabozantinib in the CABONE trial where 26% of patients with Ewing sarcoma demonstrated partial response, and 33% of patients showed non-progression of disease at six months [5], it was reasonable to attempt palliative treatment with TKI therapy after multiple failed lines of therapy. The combination of PD1-inhibitor and TKI has been shown to improve overall survival in patients with metastatic renal cell carcinoma compared to TKI monotherapy. TKIs act on many receptors/pathways associated with cancer growth and development such as VEGFR2 in angiogenesis, MET in cellular growth, and many others such as RET, AXL, KIT, FLT3, etc. But over time, TKI resistance can develop from upregulation of c-MET and AXL pathway which then promotes angiogenesis and cell proliferation [21]. This results in the upregulation of PD-L1 expression which prevents T-cell mediated immune response against cancer cells [22]. The addition of nivolumab restores the immune-mediated activity against cancer cells and acts synergistically with cabozantinib to halt metastasis.

Cabozantinib is the only VEGFR2 TKI with also inhibitory effects on c-MET receptor activity [23]. In vitro studies with osteosarcoma indicate cabozantinib has a dose-dependent inhibitory effect on c-MET pathways, which downstream inhibits AKT and ERK proteins thereby inhibiting the proliferation and migration of osteosarcoma cells. Additionally, cabozantinib alters the bone microenvironment via inhibition of RANK-positive osteosarcoma cells causing a decreased amount of free RANKL, which ultimately limits the tumor cycle induced by osteoclastogenesis [24]. The anti-PD1 antibodies negatively regulate the immunomodulatory effect of tumor cells which allows them to evade the body’s immune response. In a phase 2 study, SARCO28, various STS were treated with pembrolizumab monotherapy resulting in an 18% overall response with 55% of patients achieving progression-free survival at 12 weeks, and one patient with UPS even achieved complete remission [25]. A retrospective study of 88 patients with STS treated with various immune checkpoint inhibitors remarkably
demonstrated that UPS had the highest rate of response [26].

CONCLUSION

Considering the promising results of cabozantinib and nivolumab in various tumor types and our two patients’ significant response to therapy, we conclude that further clinical trials with this combination therapy are needed in STS patients. Given the nature of case reports, it is important to highlight the inherent limitation of small patient population thereby limiting the generalizability of the findings to a broaden population. Further research, such as randomized controlled trials, is needed to validate the findings illustrated in our case report to elevate the use of combined therapy earlier in treatment guidelines to improve morbidity and mortality in aggressive STS subtypes.

REFERENCES

Acknowledgments
The views expressed herein are those of the author(s) and do not reflect the official policy or position of Brooke Army Medical Center, the Department of Defense, the Defense Health Agency, or any agencies under the U.S. Government.

Author Contributions
My Linh D Vu – Design of the work, Acquisition of data, Analysis of data, Interpretation of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved
Andrew Berman – Acquisition of data, Drafting the work, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved
Erica Kao – Analysis of data, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved
Kristin Stoll – Interpretation of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved
Lauren Lee – Conception of the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Guarantor of Submission
The corresponding author is the guarantor of submission.

Source of Support
None.

Consent Statement
Written informed consent was obtained from the patient for publication of this article.

Conflict of Interest
Authors declare no conflict of interest.

Data Availability
All relevant data are within the paper and its Supporting Information files.

Copyright
© 2023 My Linh D Vu et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.